Rein Therapeutics
Rein Therapeutics reported revenue of $0 million in fiscal 2025. The diluted share count rose 41.8%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Rein Therapeutics lost money in fiscal 2025: a net loss of $50 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 46 | 21 | — | 13 | 3 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 10.7x | 6.5x | 4.2x | 2.4x | 0.7x |
| Quick ratio | 10.7x | 6.5x | 4.2x | 2.4x | 0.7x |
Cash flow
Projections
Project Rein Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $74,701 of Rein Therapeutics shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 27, 2026 | Rickenbach Josef H VonDirector | Bought | 4,500 | $1.07 | $4,815 | Form 4 |
| May 26, 2026 | Rickenbach Josef H VonDirector | Bought | 23,190 | $1.06 | $24,581 | Form 4 |
| May 22, 2026 | Rickenbach Josef H VonDirector | Bought | 15,950 | $1.05 | $16,748 | Form 4 |
| May 21, 2026 | Rickenbach Josef H VonDirector | Bought | 3,420 | $1.04 | $3,557 | Form 4 |
| Apr 30, 2026 | James Brian WindsorSee Remarks, Director | Bought | 25,000 | $1.00 | $25,000 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | 4.34 | −17.30 | −66.28 |
| Accruals ratio | 6.4% | −48.3% | −70.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | — | — | — |
Compare
Put Rein Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Rein Therapeutics | FY25 | — | — | — | — | — | — | |
| Aardvark Therapeutics | FY25 | — | — | — | — | — | — | Compare |
| ABVC BioPharma | FY25 | −41.9% | −2,416.0% | — | — | — | — | Compare |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue growth | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 10 | 14 | 18 | 18 | 11 | 17 | 18 | 4 | 14 | 11 |
| Operating income | −18 | −23 | −32 | −30 | −20 | −27 | −28 | −16 | −65 | −51 |
| Net income | −18 | −23 | −32 | −29 | −27 | −26 | −27 | −16 | −63 | −50 |
| Diluted EPS (US$) | −847.00 | −60.80 | −42.80 | −24.00 | −12.20 | −5.89 | −6.02 | −3.42 | −3.51 | −1.96 |
| Diluted shares (millions) | 0 | 0 | 1 | 1 | 2 | 4 | 4 | 5 | 18 | 25 |
| Cash flow | ||||||||||
| Cash from operations | −15 | −20 | −28 | −26 | −20 | −24 | −25 | −20 | −22 | −19 |
| Capital expenditure | — | 0 | 4 | 0 | 0 | 0 | — | — | — | — |
| Free cash flow | — | −21 | −32 | −27 | −20 | −24 | — | — | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 2 | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 2 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 21 | 51 | 21 | 18 | 14 | 46 | 21 | — | 13 | 3 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 22 | 53 | 30 | 26 | 16 | 48 | 22 | 106 | 62 | 24 |
| Total liabilities | 4 | 5 | 11 | 10 | 4 | 5 | 3 | 8 | 8 | 7 |
| Shareholders' equity | −112 | 48 | 20 | 16 | 12 | 44 | 19 | 98 | 54 | 17 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −93.6% | −164.8% | −193.8% | −93.3% | −87.4% | −26.9% | −82.4% | −139.9% |
| Return on assets | — | −60.5% | −76.0% | −103.4% | −127.7% | −80.7% | −77.5% | −24.6% | −74.8% | −115.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |